{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:08:32Z","timestamp":1788818912763,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"37","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA269661"],"award-info":[{"award-number":["CA269661"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA260239"],"award-info":[{"award-number":["CA260239"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA290792"],"award-info":[{"award-number":["CA290792"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA247796"],"award-info":[{"award-number":["P30CA247796"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,29]]},"DOI":"10.1038\/s41388-026-03925-3","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:42:03Z","timestamp":1785422523000},"page":"3921-3934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PROTAC-mediated targeting of IKK\u03b2 and NR4A1 for AML therapy"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0673-9888","authenticated-orcid":false,"given":"Chandra K.","family":"Maharjan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bristy R.","family":"Podder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler H.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedehalaleh","family":"Anvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanzia Islam","family":"Tithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek M.","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder K.","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-6663","authenticated-orcid":false,"given":"Guangrong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8236-0346","authenticated-orcid":false,"given":"Weizhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"3925_CR1","doi-asserted-by":"crossref","unstructured":"Roman Diaz JL, Vazquez Martinez M, Khimani F. New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches. Cancers. 2024;16:677.","DOI":"10.3390\/cancers16030677"},{"key":"3925_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438662","volume":"44","author":"Y Abaza","year":"2024","unstructured":"Abaza Y, McMahon C, Garcia JS. Advancements and Challenges in the Treatment of AML. Am Soc Clin Oncol Educ Book. 2024;44:e438662.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3925_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"3925_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00018-013-1545-4","volume":"71","author":"C Gasparini","year":"2014","unstructured":"Gasparini C, Celeghini C, Monasta L, Zauli G. NF-\u03baB pathways in hematological malignancies. Cell Mol Life Sci. 2014;71:2083\u2013102.","journal-title":"Cell Mol Life Sci"},{"key":"3925_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.critrevonc.2015.10.001","volume":"98","author":"MCJ Bosman","year":"2016","unstructured":"Bosman MCJ, Schuringa JJ, Vellenga E. Constitutive NF-\u03baB activation in AML: Causes and treatment strategies. Crit Rev Oncol Hematol. 2016;98:35\u201344.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3925_CR6","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.3390\/ijms21093070","volume":"21","author":"M Labbozzetta","year":"2020","unstructured":"Labbozzetta M, Notarbartolo M, Poma P. Can NF-\u03baB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. Int J Mol Sci. 2020;21:3070.","journal-title":"Int J Mol Sci"},{"key":"3925_CR7","doi-asserted-by":"crossref","unstructured":"Di Francesco B, Verzella D, Capece D, Vecchiotti D, Di Vito Nolfi M, Flati I, et al. NF-\u03baB: A Druggable Target in Acute Myeloid Leukemia. Cancers. 2022;14:3557.","DOI":"10.3390\/cancers14143557"},{"key":"3925_CR8","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","volume":"98","author":"ML Guzman","year":"2001","unstructured":"Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-\u03baB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301\u20137.","journal-title":"Blood"},{"key":"3925_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2004-04-1463","volume":"105","author":"C Frelin","year":"2005","unstructured":"Frelin C, Imbert V, Griessinger E, Peyron A-C, Rochet N, Philip P, et al. Targeting NF-\u03baB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 2005;105:804\u201311.","journal-title":"Blood"},{"key":"3925_CR10","doi-asserted-by":"crossref","unstructured":"Prescott JA, Cook SJ. Targeting IKK\u03b2 in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKK\u03b2 Inhibitors. Cells 2018;7:115.","DOI":"10.3390\/cells7090115"},{"key":"3925_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/ni.1976","volume":"12","author":"LC Hsu","year":"2011","unstructured":"Hsu LC, Enzler T, Seita J, Timmer AM, Lee CY, Lai TY, et al. IL-1\u03b2-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKK\u03b2. Nat Immunol. 2011;12:144\u201350.","journal-title":"Nat Immunol"},{"key":"3925_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308.","journal-title":"Signal Transduct Target Ther"},{"key":"3925_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019;18:949\u201363.","journal-title":"Nat Rev Drug Discov"},{"key":"3925_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"3925_CR15","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"3925_CR16","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.bcp.2006.08.014","volume":"72","author":"JH Lee","year":"2006","unstructured":"Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharm. 2006;72:1311\u201321.","journal-title":"Biochem Pharm"},{"key":"3925_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/13880209.2016.1241809","volume":"55","author":"K Veerappan","year":"2017","unstructured":"Veerappan K, Natarajan S, Ethiraj P, Vetrivel U, Samuel S. Inhibition of IKK\u03b2 by celastrol and its analogues - an in silico and in vitro approach. Pharm Biol. 2017;55:368\u201373.","journal-title":"Pharm Biol"},{"key":"3925_CR18","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.7150\/ijbs.85158","volume":"19","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhang R, Li W, Ma XC, Qiu F, Sun CP. I\u03baB kinase \u03b2 (IKK\u03b2): Structure, transduction mechanism, biological function, and discovery of its inhibitors. Int J Biol Sci. 2023;19:4181\u2013203.","journal-title":"Int J Biol Sci"},{"key":"3925_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308186","volume":"11","author":"Z Ni","year":"2024","unstructured":"Ni Z, Shi Y, Liu Q, Wang L, Sun X, Rao Y. Degradation-Based Protein Profiling: A Case Study of Celastrol. Adv Sci. 2024;11:2308186.","journal-title":"Adv Sci"},{"key":"3925_CR20","doi-asserted-by":"crossref","unstructured":"Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med 2024; 221:e20231519.","DOI":"10.1084\/jem.20231519"},{"key":"3925_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1158\/1541-7786.MCR-20-0707","volume":"19","author":"S Safe","year":"2021","unstructured":"Safe S, Karki K. The Paradoxical Roles of Orphan Nuclear Receptor 4A (NR4A) in Cancer. Mol Cancer Res. 2021;19:180\u201391.","journal-title":"Mol Cancer Res"},{"key":"3925_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nchembio.106","volume":"4","author":"Y Zhan","year":"2008","unstructured":"Zhan Y, Du X, Chen H, Liu J, Zhao B, Huang D, et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat Chem Biol. 2008;4:548\u201356.","journal-title":"Nat Chem Biol"},{"key":"3925_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/lifemedi\/lnad019","volume":"2","author":"ME Carelock","year":"2023","unstructured":"Carelock ME, Master RP, Kim M-C, Jin Z, Wang L, Maharjan CK, et al. Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy. Life Med. 2023;2:lnad019.","journal-title":"Life Med"},{"key":"3925_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2019.103934","volume":"128","author":"C Chen","year":"2020","unstructured":"Chen C, Li Y, Hou S, Bourbon PM, Qin L, Zhao K, et al. Orphan nuclear receptor TR3\/Nur77 biologics inhibit tumor growth by targeting angiogenesis and tumor cells. Microvasc Res. 2020;128:103934.","journal-title":"Microvasc Res"},{"key":"3925_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ygyno.2019.04.678","volume":"154","author":"K Mohankumar","year":"2019","unstructured":"Mohankumar K, Li X, Sridharan S, Karki K, Safe S. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer. Gynecol Oncol. 2019;154:218\u201327.","journal-title":"Gynecol Oncol"},{"key":"3925_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-019-05279-9","volume":"177","author":"E Hedrick","year":"2019","unstructured":"Hedrick E, Li X, Cheng Y, Lacey A, Mohankumar K, Zarei M, et al. Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists. Breast Cancer Res Treat. 2019;177:29\u201340.","journal-title":"Breast Cancer Res Treat"},{"key":"3925_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.molcel.2018.01.001","volume":"69","author":"XX Li","year":"2018","unstructured":"Li XX, Wang ZJ, Zheng Y, Guan YF, Yang PB, Chen X, et al. Nuclear Receptor Nur77 Facilitates Melanoma Cell Survival under Metabolic Stress by Protecting Fatty Acid Oxidation. Mol Cell. 2018;69:480\u201392.e487.","journal-title":"Mol Cell"},{"key":"3925_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1128\/MCB.00912-15","volume":"36","author":"E Hedrick","year":"2016","unstructured":"Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S. NR4A1 Antagonists Inhibit \u03b21-Integrin-Dependent Breast Cancer Cell Migration. Mol Cell Biol. 2016;36:1383\u201394.","journal-title":"Mol Cell Biol"},{"key":"3925_CR29","doi-asserted-by":"publisher","first-page":"e0128308","DOI":"10.1371\/journal.pone.0128308","volume":"10","author":"E Hedrick","year":"2015","unstructured":"Hedrick E, Lee SO, Kim G, Abdelrahim M, Jin UH, Safe S, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015;10:e0128308.","journal-title":"PLoS One"},{"key":"3925_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1530\/ERC-15-0063","volume":"22","author":"E Hedrick","year":"2015","unstructured":"Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocr Relat Cancer. 2015;22:831\u201340.","journal-title":"Endocr Relat Cancer"},{"key":"3925_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4388","volume":"5","author":"F Zhou","year":"2014","unstructured":"Zhou F, Drabsch Y, Dekker TJA, de Vinuesa AG, Li Y, Hawinkels LJAC, et al. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-\u03b2 signalling. Nat Commun. 2014;5:3388.","journal-title":"Nat Commun"},{"key":"3925_CR32","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1210\/me.2014-1102","volume":"28","author":"SO Lee","year":"2014","unstructured":"Lee SO, Li X, Hedrick E, Jin UH, Tjalkens RB, Backos DS, et al. Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells. Mol Endocrinol. 2014;28:1729\u201339.","journal-title":"Mol Endocrinol"},{"key":"3925_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1755-148X.2011.00843.x","volume":"24","author":"AG Smith","year":"2011","unstructured":"Smith AG, Lim W, Pearen M, Muscat GE, Sturm RA. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. Pigment Cell Melanoma Res. 2011;24:551\u201363.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3925_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nature12688","volume":"504","author":"CM Johannessen","year":"2013","unstructured":"Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504:138\u201342.","journal-title":"Nature"},{"key":"3925_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.mvr.2018.10.011","volume":"122","author":"T Ye","year":"2019","unstructured":"Ye T, Peng J, Liu X, Hou S, Niu G, Li Y, et al. Orphan nuclear receptor TR3\/Nur77 differentially regulates the expression of integrins in angiogenesis. Microvasc Res. 2019;122:22\u201333.","journal-title":"Microvasc Res"},{"key":"3925_CR36","doi-asserted-by":"publisher","first-page":"12066","DOI":"10.1073\/pnas.1018438108","volume":"108","author":"D Zhao","year":"2011","unstructured":"Zhao D, Qin L, Bourbon PM, James L, Dvorak HF, Zeng H. Orphan nuclear transcription factor TR3\/Nur77 regulates microvessel permeability by targeting endothelial nitric oxide synthase and destabilizing endothelial junctions. Proc Natl Acad Sci USA. 2011;108:12066\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3925_CR37","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-17-3102","volume":"78","author":"S Hibino","year":"2018","unstructured":"Hibino S, Chikuma S, Kondo T, Ito M, Nakatsukasa H, Omata-Mise S, et al. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance. Cancer Res. 2018;78:3027\u201340.","journal-title":"Cancer Res"},{"key":"3925_CR38","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1073\/pnas.1200090109","volume":"109","author":"MS Fassett","year":"2012","unstructured":"Fassett MS, Jiang W, D\u2019Alise AM, Mathis D, Benoist C. Nuclear receptor Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion. Proc Natl Acad Sci. 2012;109:3891\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"3925_CR39","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530\u20134.","journal-title":"Nature"},{"key":"3925_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm1579","volume":"13","author":"SE Mullican","year":"2007","unstructured":"Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, et al. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med. 2007;13:730\u20135.","journal-title":"Nat Med"},{"key":"3925_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2012.19","volume":"1","author":"SP Boudreaux","year":"2012","unstructured":"Boudreaux SP, Ramirez-Herrick AM, Duren RP, Conneely OM. Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia. Oncogenesis. 2012;1:e19.","journal-title":"Oncogenesis"},{"key":"3925_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41375-018-0174-1","volume":"33","author":"SP Boudreaux","year":"2019","unstructured":"Boudreaux SP, Duren RP, Call SG, Nguyen L, Freire PR, Narayanan P, et al. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia. 2019;33:52\u201363.","journal-title":"Leukemia"},{"key":"3925_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/biomedicines12020394","volume":"12","author":"AM Stevens","year":"2024","unstructured":"Stevens AM, Terrell M, Rashid R, Fisher KE, Marcogliese AN, Gaikwad A, et al. Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children\u2019s Hospital at Baylor College of Medicine. Biomedicines. 2024;12:394.","journal-title":"Biomedicines"},{"key":"3925_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-022-00480-0","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4:27\u201342.","journal-title":"Nat Cancer"},{"key":"3925_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s42003-024-06124-6","volume":"7","author":"MC Kim","year":"2024","unstructured":"Kim MC, De U, Borcherding N, Wang L, Paek J, Bhattacharyya I, et al. Single-cell transcriptomics unveil profiles and interplay of immune subsets in rare autoimmune childhood Sj\u00f6gren\u2019s disease. Commun Biol. 2024;7:481.","journal-title":"Commun Biol"},{"key":"3925_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26091-4","volume":"12","author":"MC Kim","year":"2021","unstructured":"Kim MC, Borcherding N, Ahmed KK, Voigt AP, Vishwakarma A, Kolb R, et al. CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nat Commun. 2021;12:5764.","journal-title":"Nat Commun"},{"key":"3925_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun S-C. NF-\u03baB signaling in inflammation. Signal Transd Target Ther. 2017;2:17023.","journal-title":"Signal Transd Target Ther"},{"key":"3925_CR48","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"3925_CR49","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.chembiol.2022.05.003","volume":"29","author":"NC Payne","year":"2022","unstructured":"Payne NC, Maksoud S, Tannous BA, Mazitschek R. A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader. Cell Chem Biol. 2022;29:1333\u201340.e1335.","journal-title":"Cell Chem Biol"},{"key":"3925_CR50","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL\u2013AF9. Nature. 2006;442:818\u201322.","journal-title":"Nature"},{"key":"3925_CR51","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1101\/gad.1143403","volume":"17","author":"A Cozzio","year":"2003","unstructured":"Cozzio A, Passegu\u00e9 E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17:3029\u201335.","journal-title":"Genes Dev"},{"key":"3925_CR52","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1182\/blood.2024028239","volume":"145","author":"B Allen","year":"2025","unstructured":"Allen B, Bottomly D, K\u00f6hnke T, Wang A, Lin H-Y, Johnson K, et al. A CEBPB\/IL-1\u03b2\/TNF-\u03b1 feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia. Blood. 2025;145:2488\u2013506.","journal-title":"Blood"},{"key":"3925_CR53","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/biom5031302","volume":"5","author":"EP Murphy","year":"2015","unstructured":"Murphy EP, Crean D. Molecular Interactions between NR4A Orphan Nuclear Receptors and NF-\u03baB Are Required for Appropriate Inflammatory Responses and Immune Cell Homeostasis. Biomolecules. 2015;5:1302\u201318.","journal-title":"Biomolecules"},{"key":"3925_CR54","doi-asserted-by":"publisher","first-page":"29256","DOI":"10.1074\/jbc.M502606200","volume":"280","author":"L Pei","year":"2005","unstructured":"Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P. Induction of NR4A Orphan Nuclear Receptor Expression in Macrophages in Response to Inflammatory Stimuli*. J Biol Chem. 2005;280:29256\u201362.","journal-title":"J Biol Chem"},{"key":"3925_CR55","doi-asserted-by":"crossref","unstructured":"McEvoy C, de Gaetano M, Giffney HE, Bahar B, Cummins EP, Brennan EP, et al. NR4A Receptors Differentially Regulate NF-\u03baB Signaling in Myeloid Cells. Front Immunol. 2017;8:7.","DOI":"10.3389\/fimmu.2017.00007"},{"key":"3925_CR56","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1210\/me.2005-0331","volume":"20","author":"L Pei","year":"2006","unstructured":"Pei L, Castrillo A, Tontonoz P. Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol. 2006;20:786\u201394.","journal-title":"Mol Endocrinol"},{"key":"3925_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41419-019-2196-7","volume":"11","author":"SM Estrada","year":"2020","unstructured":"Estrada SM, Thagard AS, Dehart MJ, Damicis JR, Dornisch EM, Ippolito DL, et al. The orphan nuclear receptor Nr4a1 mediates perinatal neuroinflammation in a murine model of preterm labor. Cell Death Dis. 2020;11:11.","journal-title":"Cell Death Dis"},{"key":"3925_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.molcel.2017.03.008","volume":"66","author":"M Hu","year":"2017","unstructured":"Hu M, Luo Q, Alitongbieke G, Chong S, Xu C, Xie L, et al. Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy. Mol Cell. 2017;66:141\u201353.e146.","journal-title":"Mol Cell"},{"key":"3925_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nchembio.1788","volume":"11","author":"L Li","year":"2015","unstructured":"Li L, Liu Y, Chen H-z, Li F-w, Wu J-f, Zhang H-k, et al. Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. Nat Chem Biol. 2015;11:339\u201346.","journal-title":"Nat Chem Biol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03925-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:03:04Z","timestamp":1788818584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03925-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":59,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2026,9,29]]}},"alternative-id":["3925"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03925-3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.X., L.W., G.Z., and W.Z. hold a patent related to NR4A1 PROTACs (US 2023\/0330237 A1).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The animal experiments were conducted in strict compliance with UF Institutional Care and Use Committee (IACUC: 202400000275). The use of two primary AML cells i.e., P401 cells (public model name AML001) and DFAM6855 (purchased from PRoXe) complies with IRBs H-3342 and 20210216.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}